Everest Organics Ltd

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive price level. Despite recent price declines and a challenging year-to-date performance, the company’s valuation metrics now present a compelling case for investors seeking value in a volatile market.

Everest Organics Ltd., a Hyderabad-based active pharmaceutical ingredients manufacturer with a market capitalisation of ₹252.00 crores, reported a net profit of ₹2.63 crores for Q4 FY26, marking a significant sequential recovery from ₹0.36 crores in Q3 FY26. However, the stock has plummeted 38.88% over the past year, significantly underperforming the Sensex's 8.40% decline, as investors remain concerned about deteriorating fundamentals and anaemic long-term growth.

Everest Organics Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators amid ongoing fundamental challenges. While the company’s financial trend shows some positive quarterly performance, concerns over long-term profitability and debt servicing continue to weigh on investor sentiment.

Everest Organics Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Everest Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 12 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Everest Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Mar 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 01 May 2026, providing investors with the latest comprehensive view of the stock’s performance and prospects.

Everest Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 20 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trend, and technical outlook.

Everest Organics Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 April 2026, providing investors with the most recent insights into the company’s performance and outlook.

While the broader market has been attempting a recovery, Everest Organics Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 209.05 on 30 Mar 2026. This decline comes despite a backdrop of positive quarterly results and a sector that has shown relative resilience.

Everest Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Everest Organics Ltd’s stock price declined to a fresh 52-week low of Rs.219 on 27 March 2026, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector and broader market weakness. The stock’s performance continues to trail key benchmarks amid subdued financial metrics and technical indicators.

Everest Organics Ltd’s stock price declined sharply to a new 52-week low of Rs.227 on 24 March 2026, marking a significant milestone in its recent downward trajectory. The stock underperformed its sector and has been on a losing streak over the past two days, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology industry.

Everest Organics Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Sell to a Strong Sell rating as of 16 Mar 2026. This revision reflects deteriorating technical indicators, subdued financial trends, and persistent valuation concerns despite some recent positive quarterly results.

Everest Organics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Everest Organics Ltd is rated Sell by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and technical outlook.

Everest Organics Ltd., a Telangana-based active pharmaceutical ingredients manufacturer with a market capitalisation of ₹374.00 crores, reported a disappointing third quarter for FY2026, with net profit collapsing 68.97% quarter-on-quarter to ₹0.36 crores from ₹1.16 crores in Q2 FY26. The sharp decline came despite marginal revenue growth on a year-on-year basis, as operating margins contracted significantly and tax expenses surged to an unusually high 65.38% of profit before tax.